You have no items in your cart.
TransCon PTH Holds Promise in Treating Hypoparathyroidism, Phase 2 Trial Shows
Hypoparathyroidism News
Ascendis Pharma’s investigational therapy TransCon PTH safely restored calcium and phosphate balance and eliminated the need for current standard care in adults with hypoparathyroidism, top-line data from a Phase 2 ... Read more